https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh
0
0
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH - Novartis
12/6/23 at 1:43am
Organization
Novartis.com
Authors
Details
62 words
Summarize
Pharmaceuticals & Biotech Health Business & Industrial Novartis FDA Fabhalta iptacopan hemoglobin improvement PNH Art Swiss
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Create an account or login to join the discussion